Dxp Enterprises (DXPE) 44.71 $DXPE DXP Enterprises

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dxp Enterprises (DXPE) 44.71 $DXPE

DXP Enterprises Expands Portfolio on Tool Supply Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 10:20AM CDT
DXP Enterprises, Inc. (DXPE) recently completed the acquisition of Tualatin, OR-based Tool Supply, Inc. Financial terms of the transaction have been kept under wraps.
ESE: 37.88 (+0.04), ROLL: 75.54 (+0.32), ASTE: 42.80 (+0.16), DXPE: 44.71 (-0.95)

Baron & Budd Overtime Lawyers File Lawsuit Against DXP Enterprises, Inc. Alleging Violations of the Fair Labor Standards Act
Business Wire - Wed Apr 08, 3:25PM CDT
The national law firm of Baron & Budd has filed a lawsuit against DXP Enterprises, Inc. alleging that the company failed to provide workers the proper amount of overtime pay in violation of the Fair Labor Standards Act (FLSA). The case is being heard in the U.S. District Court for the Southern District of Texas, Houston Division. (In Re: Case No. 4:15-cv-794)
DXPE: 44.71 (-0.95)

DXP Enterprises Announces Acquisition of Tool Supply, Inc.
Business Wire - Wed Apr 08, 8:00AM CDT
DXP Enterprises, Inc. (NASDAQ: DXPE) today announced the completion of the acquisition of Tool Supply, Inc. ("Tool Supply" , a leading distributor of state-of-the-art cutting tools, abrasives, coolants and machine shop supplies.
DXPE: 44.71 (-0.95)

BUYINS.NET: DXPE SqueezeTrigger Price is $46.34. There is $18,493,069 That Short Sellers Still Need To Cover.
M2 - Wed Apr 08, 4:42AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring DXP ENTERPRISES, INC. (NASDAQ XPE) in real time and just received an alert that DXPE is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 398300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $46.34. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
DXPE: 44.71 (-0.95)

Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 27, 12:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HYGS: 12.07 (+0.18), TRVN: 6.91 (-0.53), GLBZ: 12.40 (-0.01), MCEP: 6.13 (+0.11), DIOD: 28.02 (+0.12), DISCB: 33.69 (-0.19), HYG.TO: 14.75 (+0.15), DISCA: 33.53 (+0.05), BIND: 7.01 (-0.30), APS.TO: 7.25 (-0.65), DXPE: 44.71 (-0.95), APTO: 5.94 (-0.53), DISCK: 31.69 (-0.08), ORMP: 7.25 (-0.10), SCMP: 21.75 (+0.47), WRLD: 74.99 (+0.21), VBLT: 4.37 (-0.08), REPH: 10.71 (-0.78)

DXP Enterprises: The Correction Could Be Over, It's Time To Buy
Andy Batts - at Seeking Alpha - Tue Mar 10, 8:22PM CDT

DXPE: 44.71 (-0.95)

DXP Enterprises Down to Strong Sell on Weak Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 3:10PM CDT
Zacks Investment Research downgraded DXP Enterprises, Inc. (DXPE) to a Zacks Rank #5 (Strong Sell) on Mar 7, 2015.
IIVI: 18.75 (-0.03), ESE: 37.88 (+0.04), DXPE: 44.71 (-0.95), AOS: 65.83 (+0.41)

DXP Q4 Earnings Miss, Sales Beat on Acquisition Benefits - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 8:40AM CST
Premium industrial equipment company, DXP Enterprises, Inc. (DXPE) reported moderate results for fourth-quarter 2014.
BAH: 28.90 (+0.05), KAI: 54.52 (-0.23), DXPE: 44.71 (-0.95), ABM: 31.87 (-0.15)

DXP Enterprises' (DXPE) CEO David Little Discusses Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 10:07PM CST

DXPE: 44.71 (-0.95)

DXP Enterprises reports 4Q loss
Automated Insights - Mon Mar 02, 3:51PM CST
HOUSTON (AP) _ DXP Enterprises Inc. (DXPE) on Monday reported a fourth-quarter loss of $88.1 million, after reporting a profit in the same period a year earlier.
DXPE: 44.71 (-0.95)

DXP Enterprises misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:09PM CST

DXPE: 44.71 (-0.95)

DXP Enterprises Announces 2014 Fourth Quarter and Year End Results
Business Wire - Mon Mar 02, 3:00PM CST
--Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA" of $139.9 million, or 9.3% of sales
DXPE: 44.71 (-0.95)

Downtrend Call Working As DXP Enterprises Stock Falls 42.1% (DXPE)
Comtex SmarTrend(R) - Mon Feb 09, 9:37AM CST
SmarTrend identified a Downtrend for DXP Enterprises (NASDAQ XPE) on May 13th, 2014 at $77.20. In approximately 9 months, DXP Enterprises has returned 42.06% as of today's recent price of $44.73.
DXPE: 44.71 (-0.95)

46.7% Return Seen to Date on SmarTrend DXP Enterprises Call (DXPE)
Comtex SmarTrend(R) - Mon Feb 02, 9:14AM CST
SmarTrend identified a Downtrend for DXP Enterprises (NASDAQ XPE) on May 13th, 2014 at $77.20. In approximately 9 months, DXP Enterprises has returned 46.67% as of today's recent price of $41.17.
DXPE: 44.71 (-0.95)

What Falling Estimates & Price Mean for DXP Enterprises (DXPE) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 7:51AM CST
DXP Enterprises is one such stock that can be considered to drop as it has witnessed a significant price decline and has seen negative earnings estimate revisions
KAI: 54.52 (-0.23), DXPE: 44.71 (-0.95)

Shares of DXPE Down 48.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Jan 16, 11:02AM CST
SmarTrend identified a Downtrend for DXP Enterprises (NASDAQ XPE) on May 13th, 2014 at $77.20. In approximately 8 months, DXP Enterprises has returned 47.96% as of today's recent price of $40.17.
DXPE: 44.71 (-0.95)

Commit To Buy DXP Enterprises At $35, Earn 14.8% Annualized Using Options
at The Street - Wed Jan 14, 10:39AM CST
Investors considering a purchase of DXP Enterprises, Inc. stock, but tentative about paying the going market price of $41.07/share, might benefit from considering selling puts among the alternative strategies at their disposal.
DXPE: 44.71 (-0.95)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 5

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 9

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 8

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bryan Leon Joins Storm Properties to Elevate Acquisitions Team

Updated Category News Views 381

Storm Properties Welcomes Bryan Leon as New Hire Storm Properties Inc., recognized as a significant player in the development, ownership, and management of a variety of properties, is delighted to announce the addition of Bryan Leon to their team as Land Acquisitions Manager. This appointment comes as part of the company's ongoing strategy to strengthen its position in...

Continue Reading
Revolutionizing Trade Setups with Innovative Scanner Technology

Updated Category News Views 280

Revolutionizing Trade Setups with Innovative Scanner Technology Stock Market Guides is thrilled to introduce significant advancements to its cutting-edge stock scanner technology. The latest update empowers users by showcasing the historical track record of various trade setups it identifies, offering unparalleled insight to traders looking to enhance their market...

Continue Reading
EQT Life Sciences Champions $39 Million Investment in Aerska

Updated Category News Views 101

EQT Life Sciences Champions $39 Million Investment in Aerska Advancing RNA Therapeutics EQT Life Sciences has recently announced a significant milestone: leading a $39 million Series A financing round in Aerska. This funding will be instrumental in pushing forward Aerska’s innovative brain shuttle technology. Designed to optimize the delivery of RNA interference...

Continue Reading
NVIDIA's Anticipated Earnings Report: Key Insights for Investors

Updated Category News Views 160

Understanding NVIDIA's Upcoming Earnings Announcement NVIDIA (NASDAQ: NVDA) is set to release its much-anticipated quarterly earnings report soon. Investors are keen to understand how the company is performing and what guidance it will provide for future quarters. Analysts predict that NVIDIA will announce an earnings per share (EPS) of $0.98, which indicates the level of...

Continue Reading
Innovative Partnership Forged for Enhanced Vehicle Safety

Updated Category News Views 185

Innovative Partnership Forged for Enhanced Vehicle Safety NOVOSENSE Microelectronics, a key player in the semiconductor industry known for its high-performance analog and mixed-signal chips, is joining hands with Continental Automotive Technologies to enhance vehicle safety systems. This collaboration aims to push the envelope in developing automotive-grade sensors that...

Continue Reading